Roberto Pedraza, MD
Urology · Rockville, MDNPI 1053419614
Payments from drug & device makers
Across 193 payments — averaging $28.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$684
- Astellas Pharma US Inc$616
- AbbVie$547
- Bayer$481
- Urogen Pharma, Inc.$440
- Sumitomo Pharma America, Inc.$354
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,39798%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 7 | $684 |
| Astellas Pharma US Inc | 28 | $616 |
| AbbVie(2 entities) | 21 | $547 |
| Bayer | 18 | $481 |
| Urogen Pharma, Inc. | 17 | $440 |
| Sumitomo Pharma America, Inc. | 17 | $354 |
| Boston Scientific | 5 | $269 |
| Johnson & Johnson(2 entities) | 8 | $219 |
| Axonics, Inc. | 3 | $215 |
| Progenics Pharmaceuticals, Inc. | 4 | $188 |
| Antares Pharma, Inc. | 8 | $173 |
| Immunitybio, Inc. | 1 | $135 |
| Tolmar, Inc. | 5 | $129 |
| Endo Pharmaceuticals Inc. | 7 | $120 |
| Endo USA, Inc. | 4 | $104 |
| Merck | 4 | $89 |
| Abiomed | 1 | $81 |
| Accord Healthcare, Inc. | 3 | $64 |
| 180 Medical, Inc. | 2 | $56 |
| Myriad Genetic Laboratories, Inc. | 3 | $49 |
| Telix Pharmaceuticals | 2 | $49 |
| Halozyme Inc | 2 | $46 |
| Pfizer | 2 | $43 |
| Novartis | 2 | $43 |
| Coloplast | 3 | $43 |
| Olympus America Inc. | 2 | $38 |
| AstraZeneca | 1 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Hollister Incorporated | 2 | $32 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $28 |
| ABC Home Medical Supply, Inc. | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $17 |
| Urovant Sciences Inc | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Dentsply IH Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$508
- Axonics$160
- ANKTIVA$135
- SpaceOAR VUE System - 10mL$125
- PYLARIFY$114
How this compares
$5,532 in reported general payments places this provider in the 50th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 113 | $125,520 |
| GemtesaVibegron | 28 | $43,656 |
| Dutasteride | 287 | $14,579 |
| Tamsulosin Hcl | 493 | $11,124 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 47 | $11,046 |
| Silodosin | 76 | $9,367 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 301 | $8,064 |
| Mirabegron ErMirabegron | 14 | $7,172 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,921 |
| Finasteride | 144 | $2,641 |
| Estradiol | 34 | $2,610 |
| Doxycycline Monohydrate | 65 | $1,214 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $1,140 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $1,095 |
| Solifenacin Succinate | 16 | $985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $616 | $125,520113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $354 | $43,65628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 274 urology providers in Maryland.
Other urology in Rockville
- Matthew AllawayCumberland$20.6M
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
- Benjamin LowentrittBaltimore$994K
- Rian DicksteinHanover$750K
- Laura GiustoOwings Mills$628K
- Kenneth LangerBaltimore$610K
- Arvin GeorgeBaltimore$518K
- Julio DavalosGlen Burnie$503K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.